Photo by nci from unsplash
IL15 and TIGIT blockade enhances the natural killer (NK) cell–mediated activity against MHC-I–deficient melanoma both in vitro and in preclinical models. IL15-induced harnessing of NK cells, associated with their unleashing… Click to show full abstract
IL15 and TIGIT blockade enhances the natural killer (NK) cell–mediated activity against MHC-I–deficient melanoma both in vitro and in preclinical models. IL15-induced harnessing of NK cells, associated with their unleashing by TIGIT blockade, may represent a therapeutic approach for tumors, which lack HLA-I molecules thus escaping the CD8+ T cell–mediated control. See related article by Chauvin et al., p. 5520
Keywords:
tumor immunotherapy;
blockade il15;
tigit;
tigit blockade;
il15 tumor
Journal Title: Clinical Cancer Research
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Cancer Research
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!